<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04255602</url>
  </required_header>
  <id_info>
    <org_study_id>HP2020125</org_study_id>
    <nct_id>NCT04255602</nct_id>
  </id_info>
  <brief_title>A Study of Low and Standard-dose Ticagrelor After Intervention for ACS Patients</brief_title>
  <acronym>TIGER</acronym>
  <official_title>A Randomized Non-inferiority Study of Low-dose and Standard-dose Ticagrelor After Intervention for Acute Coronary Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Tong Ren Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai Tong Ren Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to evaluate the safety and efficacy of 60mg ticagrelor plus 100mg Aspirin to&#xD;
      prevent major adverse cardiovascular and cerebrovascular events in one years after&#xD;
      drug-eluting stents implantation for Chinese ACS patients compared with 90mg ticagrelor plus&#xD;
      100mg Aspirin&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 19, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>incidence of major adverse cardiovascular and cerebrovascular events(MACCES)</measure>
    <time_frame>Stent implantation to 12 months</time_frame>
    <description>death from coronary vascular causes,non-fatal myocardial infarction,stent thrombosis,coronary revascularization, stroke</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>bleeding events of BARC grade ≥2</measure>
    <time_frame>Stent implantation to 12 months</time_frame>
    <description>bleeding events of BARC grade ≥2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cardiovascular death</measure>
    <time_frame>Stent implantation to 12 months</time_frame>
    <description>death from coronary vascular causes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>acute myocardium infarction</measure>
    <time_frame>Stent implantation to 12 months</time_frame>
    <description>acute myocardium infarction including STEMI and nonSTEMI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>coronary revascularization</measure>
    <time_frame>Stent implantation to 12 months</time_frame>
    <description>coronary revascularization</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">2120</enrollment>
  <condition>Acute Coronary Syndrome</condition>
  <condition>Coronary Stent Implantation</condition>
  <arm_group>
    <arm_group_label>low dose ticagrelor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After treated with ticagrelor 90mg twice daily and aspirin 100mg once daily for a week,subjects will be treated with ticagrelor 60mg twice daily and aspirin 100mg once daily for until one year after drug eluting stent implantation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>standard dose ticagrelor</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>subjects will be treated with ticagrelor 90mg twice daily and aspirin 100mg once daily for a year since drug eluting stent implantation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ticagrelor 60mg</intervention_name>
    <description>Ticagrelor 60mg plus Aspirin 100mg for experimental group</description>
    <arm_group_label>low dose ticagrelor</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ticagrelor 90mg</intervention_name>
    <description>Ticagrelor 90mg plus Aspirin 100mg for active comparator group</description>
    <arm_group_label>standard dose ticagrelor</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject must be at least 18 years of age&#xD;
&#xD;
          2. Patients should have undergone successful percutaneous coronary intervention with&#xD;
             drug-eluting stent for acute coronary syndrome&#xD;
&#xD;
          3. Subject understand the study requirements and the treatment procedures and provided&#xD;
             informed consent before the procedure&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Female of childbearing potential, unless a recent pregnancy test is negative, who&#xD;
             possibly plan to become pregnant any time after enrollment into this study&#xD;
&#xD;
          2. Active bleeding&#xD;
&#xD;
          3. Known hypersensitivity or contraindication to study medications&#xD;
&#xD;
          4. Non-cardiac co-morbid conditions are present with life expectancy &lt;2 year or that may&#xD;
             result in protocol non-compliance (per site investigator's medical judgment).&#xD;
&#xD;
          5. Subjects with Cerebral hemorrhage history&#xD;
&#xD;
          6. Subjects with stroke history in half a year&#xD;
&#xD;
          7. subjects with malignant tumor&#xD;
&#xD;
          8. subjects with whom oral anticoagulants are needed&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Junbo Ge, Doctor</last_name>
    <role>Study Chair</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lei Hou, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Tongren hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lei Hou, Doctor</last_name>
    <phone>13564868096</phone>
    <email>Dr_houlei@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Junbo Ge, Doctor</last_name>
    <email>Ge.junbo@zs-hospital.sh.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Taishan people's hospital</name>
      <address>
        <city>Taishan</city>
        <state>Guangdong</state>
        <zip>529200</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>yan Chen, Doctor</last_name>
    </contact>
    <investigator>
      <last_name>yan chen, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>South East of Shandong hospital</name>
      <address>
        <city>Liaocheng</city>
        <state>Shandong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>zhongwei Jia, doctor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>zhangshan hospital, Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Junbo Ge, Doctor</last_name>
    </contact>
    <investigator>
      <last_name>Junbo Ge, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>shanghai Tongren hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200050</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lei Hou, Doctor</last_name>
    </contact>
    <investigator>
      <last_name>Lei Hou, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Caohui Qiu, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yanan Peng, Doctor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Minhang hospital, Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>201100</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Wei Hu, Doctor</last_name>
    </contact>
    <investigator>
      <last_name>Wei Hu, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ningbo 4th hospital</name>
      <address>
        <city>Xiangshan</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>jianfei Ye, master</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yanzhou branch of affiliated hospital of Jining medical university</name>
      <address>
        <city>Jining</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jian Yang</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>January 29, 2020</study_first_submitted>
  <study_first_submitted_qc>February 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2020</study_first_posted>
  <last_update_submitted>September 26, 2021</last_update_submitted>
  <last_update_submitted_qc>September 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ticagrelor</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

